Skip to main content

CryoLife Target of Unusually High Options Trading (NYSE:CRY)

Tuesday, May 4, 2021 | MarketBeat

CryoLife, Inc. (NYSE:CRY) was the recipient of unusually large options trading on Monday. Traders acquired 1,565 put options on the stock. This represents an increase of 3,030% compared to the typical daily volume of 50 put options.

In other CryoLife news, SVP Jean F. Holloway sold 1,693 shares of CryoLife stock in a transaction dated Wednesday, March 10th. The stock was sold at an average price of $25.28, for a total transaction of $42,799.04. Also, VP Dennis B. Maier sold 7,197 shares of CryoLife stock in a transaction dated Wednesday, February 17th. The stock was sold at an average price of $24.73, for a total value of $177,981.81. Following the transaction, the vice president now owns 23,211 shares in the company, valued at $574,008.03. The disclosure for this sale can be found here. Insiders own 4.70% of the company's stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CWM Advisors LLC raised its holdings in CryoLife by 18.9% during the first quarter. CWM Advisors LLC now owns 12,608 shares of the medical equipment provider's stock worth $285,000 after acquiring an additional 2,006 shares in the last quarter. Oregon Public Employees Retirement Fund raised its holdings in CryoLife by 8.2% during the first quarter. Oregon Public Employees Retirement Fund now owns 15,945 shares of the medical equipment provider's stock worth $360,000 after acquiring an additional 1,211 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in CryoLife by 49.9% during the first quarter. Exchange Traded Concepts LLC now owns 101,495 shares of the medical equipment provider's stock worth $2,292,000 after acquiring an additional 33,779 shares in the last quarter. Principal Financial Group Inc. raised its holdings in CryoLife by 1.5% during the fourth quarter. Principal Financial Group Inc. now owns 283,623 shares of the medical equipment provider's stock worth $6,697,000 after acquiring an additional 4,175 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in CryoLife by 450.8% during the fourth quarter. JPMorgan Chase & Co. now owns 75,602 shares of the medical equipment provider's stock worth $1,785,000 after acquiring an additional 61,876 shares in the last quarter. Institutional investors and hedge funds own 80.92% of the company's stock.

Shares of CryoLife stock opened at $28.32 on Tuesday. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -74.52, a price-to-earnings-growth ratio of 161.60 and a beta of 1.47. The stock's 50-day moving average is $23.26 and its 200-day moving average is $22.77. CryoLife has a one year low of $16.13 and a one year high of $30.00. The company has a debt-to-equity ratio of 0.89, a current ratio of 4.35 and a quick ratio of 3.06.

CryoLife (NYSE:CRY) last released its earnings results on Thursday, April 29th. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. CryoLife had a positive return on equity of 1.86% and a negative net margin of 5.45%. On average, equities analysts expect that CryoLife will post 0.01 EPS for the current year.

CRY has been the topic of several recent analyst reports. Needham & Company LLC lifted their target price on CryoLife from $33.00 to $38.00 and gave the stock a "buy" rating in a report on Friday. Zacks Investment Research upgraded CryoLife from a "sell" rating to a "hold" rating in a report on Wednesday, April 14th.

CryoLife Company Profile

CryoLife, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system.

Recommended Story: After-Hours Trading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What is a Tariff?


7 Undervalued Stocks That Deserve More Attention

With the Dow Jones Industrial Average (DJIA) hitting new highs seemingly every day, it may seem like the wrong time to be looking at undervalued stocks. Or is it?

From cannabis to cryptocurrencies, and let’s not forget electric vehicles the market seems to be blowing bubbles wherever you look. And that’s why now may be exactly the right time to zig while the market is sagging. And that means looking for undervalued stocks.

But finding undervalued stocks is subjective. Some analysts use specific fundamental metrics. Others use technical analysis.

However, the general idea is that you’re looking for stocks that are trading below their fair value.

In some cases, these may be stocks whose financials are stronger than other stocks in their sector, but it’s trading at a lower price. In other cases, a company may have potential that is not reflected in its stock price. Put another way, undervalued stocks are stocks that have room to grow. That’s why they deserve a place in your portfolio.

And that’s why we’ve put together this special presentation on stocks that are undervalued right at this time. An investment in these companies is likely to be rewarded because the stocks are moving under the radar from the broader market.

View the "7 Undervalued Stocks That Deserve More Attention".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.